Benchmarking a commercial proton therapy solution: The Paul Scherrer institut experience.

CONCLUSION: Both systems showed a good capacity to produce satisfactory plans, with Eclipse™ being able to achieve better target coverage and plan homogeneity without compromising OARs.
ADVANCES IN KNOWLEDGE: A benchmark between a clinically tested and validated system with a commercial solution is of interest for emerging proton therapy, equipped with commercial systems and no previous experience with PBS.
PMID: 31944827 [PubMed - as supplied by publisher]

Source: The British Journal of Radiology - January 15, 2020 Category: Radiology Authors: Rosas S, Belosi FM, Bizzocchi N, Boehlen T, Zepter S, Morach P, Lomax AJ, Weber DC, Hrbacek J Tags: Br J Radiol Source Type: research